The anti ‐convulsants lacosamide, lamotrigine, and rufinamide reduce myotonia in isolated human and rat skeletal muscle
ConclusionThese findings suggest that lamotrigine and rufinamide could be considered for anti‐myotonic treatment in myotonia congenita. Muscle Nerve, 2016 (Source: Muscle and Nerve)
Source: Muscle and Nerve - February 22, 2017 Category: Internal Medicine Authors: Martin Skov, Frank V. Paoli, Ole B. Nielsen, Thomas H. Pedersen Tags: Research Article Source Type: research
Lennox-Gastaut Syndrome: a Current Review
AbstractPurpose of ReviewThe diagnosis of Lennox-Gastaut syndrome (LGS), a refractory epileptic encephalopathy, is often made late into disease progression based on the absence of classic EEG abnormalities or typical seizure types at disease onset. The goal of this article is to serve as a general review of LGS for the non-neurologist. As such, we hope to elucidate how a diagnosis is made, highlight novel treatment options, and encourage collaborative treatment decisions between care givers, primary care physicians, neurologists, and psychiatrists.Recent FindingsAlthough a relatively limited number of randomized clinical t...
Source: Current Pediatrics Reports - February 21, 2017 Category: Pediatrics Source Type: research
Evaluate the Efficacy and Safety of Anti ‐epileptic Medications for Partial Seizures of Epilepsy: A Network Meta‐analysis
This article is protected by copyright. All rights reserved (Source: Journal of Cellular Biochemistry)
Source: Journal of Cellular Biochemistry - February 17, 2017 Category: Biochemistry Authors: Teng Zhao, Xuemin Feng, Jingyao Liu, Jiguo Gao, Chunkui Zhou Tags: Article Source Type: research
Dosing Considerations for Rufinamide in Patients With Lennox-Gastaut Syndrome: Phase III Trial Results and Real-World Clinical Data
Conclusions A lower dose and slower titration schedule (“low and slow”) may reduce incidence of AEs without compromising efficacy of rufinamide in LGS. (Source: Seizure)
Source: Seizure - February 16, 2017 Category: Neurology Source Type: research
Dosing considerations for rufinamide in patients with Lennox –Gastaut syndrome: Phase III trial results and real-world clinical data
Lennox –Gastaut syndrome (LGS) is one of the most severe forms of childhood-onset epilepsy, accounting for approximately 1% to 4% of all childhood epilepsy cases, with peak onset occurring between the ages of 3 and 5 years [1–3]. Although the etiology of LGS is frequently unknown, the condition is char acterized by a triad of symptoms, including impairment of cognitive function, slow spike-and-wave complexes on electroencephalogram (EEG) recordings, and multiple seizure types, making it particularly difficult to control [1,3]. (Source: Seizure: European Journal of Epilepsy)
Source: Seizure: European Journal of Epilepsy - February 15, 2017 Category: Neurology Authors: Sanjeev Kothare, Gerhard Kluger, Rajesh Sachdeo, Betsy Williams, Omar Olhaye, Carlos Perdomo, Francesco Bibbiani Source Type: research
Dosing Considerations for Rufinamide in Patients With Lennox-Gastaut Syndrome: Phase III Trial Results and Real-World Clinical Data
Lennox-Gastaut syndrome (LGS) is one of the most severe forms of childhood-onset epilepsy, accounting for approximately 1% to 4% of all childhood epilepsy cases, with peak onset occurring between the ages of 3 and 5 years [1 –3]. Although the etiology of LGS is frequently unknown, the condition is characterized by a triad of symptoms, including impairment of cognitive function, slow spike-and-wave complexes on electroencephalogram (EEG) recordings, and multiple seizure types, making it particularly difficult to contro l [1,3]. (Source: Seizure: European Journal of Epilepsy)
Source: Seizure: European Journal of Epilepsy - February 15, 2017 Category: Neurology Authors: Sanjeev Kothare, Gerhard Kluger, Rajesh Sachdeo, Betsy Williams, Omar Olhaye, Carlos Perdomo, Francesco Bibbiani Source Type: research
Current Treatment Options for Early-Onset Pediatric Epileptic Encephalopathies.
Abstract
OPINION STATEMENT: The management of early-onset, genetically determined epilepsies is often challenging. First-line anti-epileptic drugs (AEDs) often include phenobarbital, phenytoin, oxcarbazepine, carbamazepine, clonazepam, levetiracetam, and valproic acid. Combinations of medications are used in these patients with often intractable seizures, and they include topiramate, clobazam, felbamate, lacosamide, lamotrigine, rufinamide, vigabatrin, ACTH, oral steroids, and the ketogenic diet. Vagus nerve stimulator therapy offers some relief in selected patients. Surgical procedures, such as multiple s...
Source: Epilepsy Curr - September 7, 2016 Category: Neurology Authors: Shbarou R Tags: Curr Treat Options Neurol Source Type: research
Current Treatment Options for Early-Onset Pediatric Epileptic Encephalopathies
Opinion statementThe management of early-onset, genetically determined epilepsies is often challenging. First-line anti-epileptic drugs (AEDs) often include phenobarbital, phenytoin, oxcarbazepine, carbamazepine, clonazepam, levetiracetam, and valproic acid. Combinations of medications are used in these patients with often intractable seizures, and they include topiramate, clobazam, felbamate, lacosamide, lamotrigine, rufinamide, vigabatrin, ACTH, oral steroids, and the ketogenic diet. Vagus nerve stimulator therapy offers some relief in selected patients. Surgical procedures, such as multiple subpial transections (MSTs), ...
Source: Current Treatment Options in Neurology - September 4, 2016 Category: Neurology Source Type: research
Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis
ConclusionOrphan drug development in the US and in the EU delivered only few molecular entities to treat rare seizure disorders. The development programs focused on already approved antiepileptic drugs or alternative pharmaceutical formulations. Most orphan drugs approved in the US are not approved in the EU to treat rare seizures although some were introduced after 2000 when the EU adopted the Orphan Drug Regulation. (Source: PLoS One)
Source: PLoS One - August 23, 2016 Category: Biomedical Science Authors: Jan Henje D öring Source Type: research
9. Drop attacks in Lennox –Gastaut Syndrome: Is Rufinamide the answer?
The purpose of this study is to determine whether Banzel (Rufinamide) improves the control of drop attacks in patients with Lennox –Gastaut Syndrome, and whether it controls other seizure types in LGS. (Source: Clinical Neurophysiology)
Source: Clinical Neurophysiology - August 5, 2016 Category: Neuroscience Authors: Boris Yakubov, Janet Shaw, Jose Embuido, Paul Hwang Source Type: research
From alcohol to 1,2,3-triazole via a multi-step continuous-flow synthesis of a rufinamide precursor
Green Chem., 2016, Advance ArticleDOI: 10.1039/C6GC01133K, PaperSvetlana Borukhova, Timothy Noel, Bert Metten, Eric de Vos, Volker HesselBringing the strongest suits of flow chemistry together to deliver the greenest possible process for continuous manufacturing of a rufinamide precursor.To cite this article before page numbers are assigned, use the DOI form of citation above.The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Green Chem. latest articles)
Source: RSC - Green Chem. latest articles - June 8, 2016 Category: Chemistry Authors: Svetlana Borukhova Source Type: research
Emerging Anti-Epileptic Drugs for Severe Pediatric Epilepsies
The medical management of the epilepsy syndromes of early childhood (eg., infantile spasms, Dravet syndrome, Lennox-Gastaut syndrome, etc.) is challenging; and requires careful evaluation, classification and treatment. Pharmacological treatment continues to be the mainstay of therapy for these children, and as such it is important for the clinician to be familiar with the role of new anti-epileptic drugs (AEDs). This review reports the clinical trial data and personal experience in treating the severe epilepsies of childhood with the recently FDA approved AEDs (vigabatrin, rufinamide, perampanel, clobazam) and those in cli...
Source: Seminars in Pediatric Neurology - June 4, 2016 Category: Neurology Authors: Basanagoud Mudigoudar, Sarah Weatherspoon, James W. Wheless Source Type: research
Emerging Antiepileptic Drugs for Severe Pediatric Epilepsies
This article reports the clinical trial data and personal experience in treating the severe epilepsies of childhood with the recently Food and Drug Administration-approved new antiepileptic drugs (vigabatrin, rufinamide, perampanel, and clobazam) and those in clinical trials (cannabidiol, stiripentol, and fenfluramine). (Source: Seminars in Pediatric Neurology)
Source: Seminars in Pediatric Neurology - June 4, 2016 Category: Neurology Authors: Basanagoud Mudigoudar, Sarah Weatherspoon, James W. Wheless Source Type: research
Treatment of Adults with Lennox –Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of Rufinamide
Conclusion < /h3 > < p class= " a-plus-plus " > Rufinamide demonstrated favorable efficacy and was generally well tolerated when used as adjunctive treatment for adults with LGS. < /p > < /span > < span class= " a-plus-plus abstract-section id-a-sec5 " > < h3 class= " a-plus-plus " > Funding < /h3 > < p class= " a-plus-plus " > Eisai. < /p > < /span > (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 31, 2016 Category: Neurology Source Type: research
